Table 2.

Adjusted cause-specific hazard ratio for 25% decrease in eGFR and ESKD in patients with CKD and hepatitis C infection compared with those with CKD alone

Characteristics	25% Decline in eGFR			ESKD
	No. of Patients with 25% Decrease	HRa,b	95% CI	No. of Patients with ESKD	HRa,b	95% CI
Cohort
HCV and CKD	915	1.87	1.75 to 2.00	162	1.93	1.64 to 2.27
CKD only	65,133	1.00	Reference	5240	1.00	Reference
Age, yr	66,048	1.00	1.00 to 1.00	5402	0.93	0.93 to 0.94
Sex
Women	35,529	1.01	0.99 to 1.03	2265	0.65	0.61 to 0.68
Men	30,519	1.00	Reference	3137	1.00	Reference
Race
Asian/Pacific Islander	5246	1.01	0.98 to 1.04	514	1.64	1.48 to 1.81
Black	11,123	1.28	1.25 to 1.31	1594	2.81	2.61 to 3.01
Hispanic	12,613	1.21	1.19 to 1.24	1685	2.31	2.15 to 2.48
Others	174	0.85	0.73 to 0.98	28	2.43	1.67 to 3.52
White	36,892	1.00	Reference	1581	1.00	Reference
Baseline comorbidity
Diabetes mellitus	25,417	1.71	1.68 to 1.74	3062	2.80	2.64 to 2.96
Hypertension	42,594	1.24	1.22 to 1.26	2791	0.74	0.70 to 0.78
HIV	250	1.44	1.26 to 1.63	44	1.24	0.90 to 1.71
Hepatitis B	209	1.16	1.01 to 1.33	27	1.17	0.78 to 1.75
Myocardial infarction	2082	1.48	1.42 to 1.55	161	1.32	1.13 to 1.55
ESLD	449	3.75	3.41 to 4.12	52	2.89	2.19 to 3.81
Baseline eGFR	66,048	1.02	1.02 to 1.02	5402	0.94	0.94 to 0.95

HR, hazard ratio; 95% CI, 95% confidence interval; HCV, hepatitis C virus; ESLD, end-stage liver disease.

^aFollow-up time is censored at the time of the start of dialysis, liver/kidney transplant, HCV treatment, death, disenrollment from Kaiser Permanente health plan, or the end of the study period (December 31, 2014); ESKD analyses censored on liver transplant, HCV treatment, death, disenrollment from Kaiser Permanente health plan, or the end of the study period.

^bPatients with baseline eGFR<15 ml/min per 1.73 m² were excluded: CKD only, n=151,174; HCV and CKD, n=1534.